|
Market Closed -
NYSE
16:00:00 2026-10-19 EDT
|
5-day change | 1st Jan Change | ||
| 0.9528 USD | -2.61% |
|
-0.14% | -42.95% |
| 09-30 | EARNINGS: Generation Essentials interim profit jumps to USD28 million | AN |
| 08-07 | Lineage Cell Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 |
Company Valuation: Lineage Cell Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 413 | 198.9 | 190.7 | 110.8 | 404.7 | 241 | - | - |
| Change | - | -51.84% | -4.09% | -41.93% | 265.38% | -40.46% | - | - |
| Enterprise Value (EV) | 413 | 198.9 | 190.7 | 110.8 | 404.7 | 241 | 241 | 241 |
| Change | - | -51.84% | -4.09% | -41.93% | 265.38% | -40.46% | 0% | 0% |
| P/E | -9.42x | -7.8x | -9.08x | -5.58x | -5.96x | -15.9x | -7.42x | 30.1x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.2x | 0.5x | 0.2x | -0x | 0.2x | -0x | -0x |
| Capitalization / Revenue | 95.1x | 13.5x | 21.3x | 11.7x | 27.8x | 15.9x | 14.3x | 4.03x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 15.9x | 14.3x | 4.03x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -7.16x | -8.19x | -7.86x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -7.6x | -6.84x | 36.7x |
| EV / FCF | - | 0x | -0x | -0x | -0x | -19.4x | -25.8x | 77.7x |
| FCF Yield | - | 0.32% | -15.3% | -21.4% | -4.8% | -5.15% | -3.88% | 1.29% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.26 | -0.15 | -0.12 | -0.09 | -0.28 | -0.06 | -0.1283 | 0.0317 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 4.341 | 14.7 | 8.945 | 9.499 | 14.56 | 15.19 | 16.83 | 59.72 |
| EBITDA 1 | -48.34 | -21.79 | -24.04 | -20.87 | -35.92 | -33.64 | -29.41 | -30.66 |
| EBIT 1 | -49.21 | -22.52 | -24.73 | -21.48 | -36.62 | -31.71 | -35.22 | 6.562 |
| Net income 1 | -43.02 | -26.27 | -21.49 | -18.61 | -63.53 | -22.64 | -34.44 | 8.605 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 2.4500 | 1.1700 | 1.0900 | 0.5025 | 1.6700 | 0.9528 | 0.9528 | 0.9528 |
| Nbr of stocks (in thousands) | 168,558 | 169,976 | 174,987 | 220,416 | 242,328 | 252,907 | - | - |
| Announcement Date | 3/10/22 | 3/9/23 | 3/7/24 | 3/10/25 | 3/5/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -15.88x | - | - | - | 241M | |
| 19.06x | 6.78x | 13.59x | 1.56% | 65.83B | |
| 35.71x | 6.35x | 18.96x | 0.91% | 51.87B | |
| 27.56x | 7.53x | 23.84x | 0.05% | 51.2B | |
| 33.88x | 3.31x | 14.28x | -.--% | 43.76B | |
| 48.73x | 5.61x | 30.83x | -.--% | 42.09B | |
| -18.92x | 193.08x | -20x | -.--% | 39.04B | |
| 29.6x | 8.38x | 21.69x | 0.36% | 34B | |
| 29.17x | 6.17x | 16.01x | -.--% | 25.2B | |
| 31.2x | 5.77x | 19.4x | -.--% | 22.8B | |
| Average | 22.01x | 27.00x | 15.40x | 0.32% | 37.6B | |
| Weighted average by Cap. | 25.96x | 25.69x | 15.50x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- LCTX Stock
- Valuation Lineage Cell Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
